Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-268019-b versus COMIRNATY as fourth COVID-19 booster in adults aged 60 years or older
jRCT2031220224Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing S-268019-b fourth-dose arm with COMIRNATY fourth-dose arm (2 arms). Primary endpoints: SARS-CoV-2 neutralizing antibody titer at 28 days after fourth vaccination, Incidence of adverse events and 6 more. Started Jul 2022; status: completed.
02
Drugs
S-268019-btozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031220224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220224.